About: Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19
Creator	Aguzzi, Adriano Huber, Lars Zinkernagel, Annelies Adamo, Sarah Boyman, Onur Bächli, Esther Cervia, Carlo Nilsson, Jakob Raeber, Miro Rudiger, Alain Schaer, Dominik Stüssi-Helbling, Melina Zurbuchen, Yves Bosshard, Philipp Wolfensberger, Aline De Cecco, Elena Emmenegger, Marc Hasler, Sara Held, Ulrike Probst-Müller, Elsbeth Rampini, Silvana Schreiner, Jens Valaperti, Alan
Source	BioRxiv
abstract	Background Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes an acute illness termed coronavirus disease 2019 (COVID-19). Humoral immune responses likely play an important role in containing SARS-CoV-2, however, the determinants of SARS-CoV-2-specific antibody responses are unclear. Methods Using immunoassays specific for the SARS-CoV-2 spike protein, we determined SARS-CoV-2-specific immunoglobulin A (IgA) and immunoglobulin G (IgG) in sera and mucosal fluids of two cohorts, including patients with quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR)-confirmed SARS-CoV-2 infection (n = 56; median age 61 years) with mild versus severe COVID-19, and SARS-CoV-2-exposed healthcare workers (n = 109; median age 36 years) with or without symptoms and tested negative or positive by RT-qPCR. Findings On average, SARS-CoV-2-specific serum IgA titers in mild COVID-19 cases became positive eight days after symptom onset and were often transient, whereas serum IgG levels remained negative or reached positive values 9–10 days after symptom onset. Conversely, patients with severe COVID-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers as a function of duration since symptom onset, independent of patient age and comorbidities. Very high levels of SARS-CoV-2-specific serum IgA correlated with severe acute respiratory distress syndrome (ARDS). Interestingly, some of the SARS-CoV-2-exposed healthcare workers with negative SARS-CoV-2-specific IgA and IgG serum titers had detectable SARS-CoV-2-specific IgA antibodies in their nasal fluids and tears. Moreover, SARS-CoV-2-specific IgA levels in nasal fluids of these healthcare workers were inversely correlated with patient age. Interpretation These data show that systemic IgA and IgG production against SARS-CoV-2 develops mainly in severe COVID-19, with very high IgA levels seen in patients with severe ARDS, whereas mild disease may be associated with transient serum titers of SARS-CoV-2-specific antibodies but stimulate mucosal SARS-CoV-2-specific IgA secretion. The findings suggest four grades of antibody responses dependent on COVID-19 severity.
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1101/2020.05.21.108308
has license	biorxiv
sha1sum (hex)	207519580c330ebeab11c16f89d730497e352491
schema:url	https://doi.org/10.1101/2020.05.21.108308
resource representing a document's title	Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19
schema:publication	bioRxiv
resource representing a document's body	covid:207519580c330ebeab11c16f89d730497e352491#body_text
is schema:about of	named entity 'antibody' named entity 'severe' named entity 'mild' named entity 'secretion' named entity 'coronavirus disease 2019' named entity 'COVID' named entity 'antibody' named entity 'saliva' named entity 'IgG' named entity 'antibody response' named entity 'serum levels' named entity 'IgG' named entity 'healthcare workers' named entity 'IgA' named entity 'non-parametric' named entity 'Becton Dickinson' named entity 'virus' named entity 'protein' named entity 'virus' named entity 'COVID-19' named entity 'COVID' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'COVID' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'ARDS' named entity 'immunoglobulin' named entity 'SARS' named entity 'saliva' named entity 'serum levels' named entity 'mucosa' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'IgA' named entity 'healthcare workers' named entity 'nasal cavities' named entity 'protein' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'IgG' named entity 'virus' named entity 'seronegative' named entity 'ACE2' named entity 'IgA' named entity 'IgA production' named entity 'HCW' named entity 'immunoassay' named entity 'biomarker' named entity 'antigen' named entity 'IgA' named entity 'homology' named entity 'hypertension' named entity 'IgG' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'cough' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software